Company intelligence / Profile preview

NephroSant

Brisbane, California, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

NephroSant’s flagship product, QSant™, is a non-invasive urine test that quantifies the risk of kidney transplant rejection using six urinary biomarkers. The test has been clinically validated in over 1,000 patient samples and is fully reimbursed by Medicare when ordered by a healthcare professional. Real-world experience from the Early Access Program supports its accuracy, ease of use, and convenience for both physicians and patients. Ongoing large-scale studies are further validating its utility in post-transplant care.

Therapeutic areas: ImmunologyNephrology
Modalities: Diagnostic testDevice (urine-based assay)Algorithm-based risk scoring (Q-Score)
Industry: Molecular Diagnostics

Drug pipeline

1 asset

QSant

Commercial

Indications: Kidney transplant rejection

Beyond the preview

Go deeper on NephroSant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NephroSant.

Explore the full profile